^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    KT-413 (IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ICML 2021
    Title:

    013 | KT-413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE-AGENT AND COMBINATION REGRESSIONS IN MYD88MT LYMPHOMA MODELS

    Published date:
    06/09/2021
    Excerpt:
    KT-413 also showed strongly additive activity in combination with rituximab or BTK inhibitors in MYD88MT OCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88MT DLBCL.